So we were very close. We only managed to trial L
Post# of 154595
(Total Views: 437)
Posted On: 05/08/2025 2:35:43 AM
So we were very close. We only managed to trial Leron against 28 msTNBC patients. Why was that?
NP quickly filed for BTD -- too quickly, before he even had a final mOS or could compare long-term survival as we can now.
My69 was right that this was the early Covid era, and as we all know NP quickly swiveled toward trying to get Leron approved for Covid. But Covid also hurt the msTNBC trial. I've related here the story of an old friend of mine who'd failed several lines of treatment; her doctor erroneously told her there were side effects, but stronger deterrent was the fact that the first treatment in Leron msTNBC had to take place at Dr. Jay's Quest clinic in SF. My friend, being of course sick, did not want to take a long flight to SF during Covid.
I'm sure this was a deterrent for a number of others. I believe one of the reasons why Leron didn't get breakthrough designation was due to the tiny size of the trial. NP at fault for impatience, but Covid was part of the problem.
So it's just amazing that in this small sample -- with a good number of patients started out on "half useless" (Ohm) dosage, and all of them with cancer so advanced that they'd failed three earlier lines of treatment -- the long-term survival rates are "25 times" (Ohm) better than Troldelvy's. Wow.
NP quickly filed for BTD -- too quickly, before he even had a final mOS or could compare long-term survival as we can now.
My69 was right that this was the early Covid era, and as we all know NP quickly swiveled toward trying to get Leron approved for Covid. But Covid also hurt the msTNBC trial. I've related here the story of an old friend of mine who'd failed several lines of treatment; her doctor erroneously told her there were side effects, but stronger deterrent was the fact that the first treatment in Leron msTNBC had to take place at Dr. Jay's Quest clinic in SF. My friend, being of course sick, did not want to take a long flight to SF during Covid.
I'm sure this was a deterrent for a number of others. I believe one of the reasons why Leron didn't get breakthrough designation was due to the tiny size of the trial. NP at fault for impatience, but Covid was part of the problem.
So it's just amazing that in this small sample -- with a good number of patients started out on "half useless" (Ohm) dosage, and all of them with cancer so advanced that they'd failed three earlier lines of treatment -- the long-term survival rates are "25 times" (Ohm) better than Troldelvy's. Wow.
(12)
(0)